Cloud contact center solution provider 3CLogic has apparently declared a Series B financing round worth USD 9 million. Reliable reports claim that the round was mainly led by True Blue Partners and Capitan Investment Partners, while the oth....

Leuven-based biotech firm miDiagnostics has recently concluded a €14 million investment round. The funding round was led by leading life science and technology investors, including Dr. Ir. Urbain Vandeurzen and Dr. Rudi Pauwels, as wel....

As the coronavirus pandemic reaches community level, prominent companies have come forward to aid medical researchers in accelerating their drug development process. ATUM, an American biotechnology firm, recently made a similar move when it....

InMed Pharmaceuticals Inc., a leading biopharmaceutical company which develops medications targeting diseases with unmet needs, has reportedly announced the filing of CTA (Clinical Trial Application) in the Netherlands to commence a second ....

Vapotherm, Inc., a global medical technology firm developing and manufacturing proprietary Hi-VNI Technology products, has reportedly announced an update on its business in response to the COVID-19 pandemic. Sources cite that, as result of....

As the number of COVID-19 cases grows across Asian countries, several global organizations are stepping up to help curb the growing spread of the disease by offering several aids such as masks, check-up kits, and other necessary things. Al....

The pharmaceutical firm will prioritize resources towards COVID-19 pandemic Phase 2 trial in MS patients will commence once the hospitals have enough research capacity Switzerland based biopharmaceutical firm- GeNeuro has recently a....

· AI-enabled innovative technology is derived based on analysis and insights studied during the initial virus breakout · Video conferencing and real-time AI language translations, aimed at building a platform wh....

Saniona, a renowned biopharmaceutical firm focusing on rare disorders of the central nervous system, has reportedly announced that the last patient has successfully completed the last visit in the company’s six-month, double blind Pha....

CERo Therapeutics, Inc., the privately-owned biopharma firm, recently announced that it will be collaborating for research with Lyell Immunopharma, Inc. for the development of next-gen cell-based immunotherapy solutions to treat solid tumor....